Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Solidago canadensis pollen is a non-standardized allergenic extract derived from the pollen of the Canada goldenrod plant. Marketed by ALK-Abello, Inc. under the brand name Goldenrod, it is a biological product that has been available since 1965. [1] The product is administered via subcutaneous injection and serves two main purposes: it is used in diagnostic skin tests to confirm sensitivity to goldenrod pollen, and it is used as a hyposensitization therapy (immunotherapy) to treat patients with allergic reactions. The immunotherapy works by exposing the patient to controlled, increasing doses of the pollen allergens, which modulates the immune system to reduce allergic sensitivity over time. [5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Solidago canadensis pollen.